(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are BioCardia, AGBA Acquisition Limited, and Acutus Medical.

Rank	Financial Asset	Price	Change	Updated (EST)
1	BioCardia (BCDAW)	0.02	55.04%	2024-02-21 14:23:06
2	AGBA Acquisition Limited (AGBAW)	0.02	25%	2024-02-21 01:44:05
3	Acutus Medical (AFIB)	0.24	21.21%	2024-02-21 01:17:06
4	Aprea Therapeutics (APRE)	6.28	12.34%	2024-02-21 09:08:06
5	BOQI International Medical (BIMI)	3.70	11.11%	2024-02-21 15:49:06
6	Antero Resources (AR)	25.62	9.46%	2024-02-21 15:52:32
7	Garmin (GRMN)	133.61	8.85%	2024-02-21 15:12:46
8	AC Immune SA (ACIU)	3.33	8.82%	2024-02-21 00:23:05
9	Southwestern Energy (SWN)	7.09	7.34%	2024-02-21 15:59:04
10	Akari Therapeutics Plc (AKTX)	2.39	6.7%	2024-02-21 03:23:05

The three biggest losers today are Palo Alto Networks, Matterport
, and Matterport
.

Rank	Financial Asset	Price	Change	Updated (EST)
1	Palo Alto Networks (PANW)	262.18	-28.38%	2024-02-21 15:57:43
2	Matterport (MTTR)	2.07	-18.44%	2024-02-21 15:23:16
3	Matterport (MTTR)	2.07	-18.44%	2024-02-21 15:23:16
4	Avinger (AVGR)	4.39	-17.97%	2024-02-21 13:06:05
5	AirNet Technology (ANTE)	1.01	-16.53%	2024-02-21 07:41:06
6	Aptorum Group Limited (APM)	1.62	-16.06%	2024-02-21 07:48:06
7	Zscaler (ZS)	213.16	-14.41%	2024-02-21 15:18:01
8	ATIF Holdings Limited (ATIF)	0.97	-14.16%	2024-02-21 11:11:07
9	Aravive (ARAV)	0.04	-13.39%	2024-02-21 09:14:06
10	Canaan (CAN)	1.88	-12.79%	2024-02-21 15:15:59

Winners today

1. BioCardia (BCDAW) – 55.04%

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

NASDAQ ended the session with BioCardia jumping 55.04% to $0.02 on Wednesday while NASDAQ fell 0.32% to $15,580.87.

Earnings Per Share

As for profitability, BioCardia has a trailing twelve months EPS of $-3.2.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -728.95%.

More news about BioCardia.

2. AGBA Acquisition Limited (AGBAW) – 25%

AGBA Group Holding Limited focuses on operating a full-service platform to banks, other financial institutions, brokers, and individual financial advisors to advise and serve its retail clients. The company offers a range of financial products, such as life insurance, pensions, property-casualty insurance, mutual funds, money lending, and real estate agency services. It also operates an health and wealth management platform that offers a range of services and value-added information in health, insurance, investments, and social sharing. The company is based in Wan Chai, Wan Chai.

NASDAQ ended the session with AGBA Acquisition Limited rising 25% to $0.02 on Wednesday, after five successive sessions in a row of losses. NASDAQ slid 0.32% to $15,580.87, after two successive sessions in a row of losses, on what was a somewhat bearish trend exchanging session today.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10969.8%.

Yearly Top and Bottom Value

AGBA Acquisition Limited’s stock is valued at $0.02 at 16:32 EST, way above its 52-week high of $0.02.

More news about AGBA Acquisition Limited.

3. Acutus Medical (AFIB) – 21.21%

Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is based in Carlsbad, California.

NASDAQ ended the session with Acutus Medical rising 21.21% to $0.24 on Wednesday, after two consecutive sessions in a row of gains. NASDAQ slid 0.32% to $15,580.87, after two successive sessions in a row of losses, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Acutus Medical has a trailing twelve months EPS of $-1.12.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -73.28%.

Moving Average

Acutus Medical’s worth is way above its 50-day moving average of $0.20 and way below its 200-day moving average of $0.54.

Revenue Growth

Year-on-year quarterly revenue growth grew by 43.7%, now sitting on 19.66M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Acutus Medical’s EBITDA is -0.44.

More news about Acutus Medical.

4. Aprea Therapeutics (APRE) – 12.34%

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.

NASDAQ ended the session with Aprea Therapeutics jumping 12.34% to $6.28 on Wednesday, after two sequential sessions in a row of gains. NASDAQ slid 0.32% to $15,580.87, after two sequential sessions in a row of losses, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Aprea Therapeutics has a trailing twelve months EPS of $12.31.

PE Ratio

Aprea Therapeutics has a trailing twelve months price to earnings ratio of 0.51. Meaning, the purchaser of the share is investing $0.51 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.87%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 16.3% and 85.1%, respectively.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Aprea Therapeutics’s EBITDA is 3.75.

Volume

Today’s last reported volume for Aprea Therapeutics is 22711 which is 58.32% above its average volume of 14345.

Moving Average

Aprea Therapeutics’s worth is way above its 50-day moving average of $5.14 and way higher than its 200-day moving average of $4.12.

More news about Aprea Therapeutics.

5. BOQI International Medical (BIMI) – 11.11%

BIMI International Medical Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China. The company operates in four segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies. It distributes Stryker spinal products, Olympus endoscopes, imported imaging products, and diagnostic imaging equipment to drug stores, private clinics, pharmaceutical dealers, and hospitals in the Southwest region of the People's Republic of China. The company also distributes varieties of products, including raw ingredients for pharmaceutical products, antibiotics, cardiovascular drugs, and anti-obesity medicines. In addition, it offers prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines, personal and family care products, medical devices, and miscellaneous items under the Lijiantang Pharmacy brand name. Further, the company provides medical services in the hospitals, as well as IT research and development services. It sells its medicine and other healthcare products to customers through its directly owned stores. The company was formerly known as BOQI International Medical Inc. and changed its name to BIMI International Medical Inc. in June 2021. BIMI International Medical Inc. was incorporated in 2000 and is headquartered in New York, New York.

NASDAQ ended the session with BOQI International Medical rising 11.11% to $3.70 on Wednesday, after two sequential sessions in a row of gains. NASDAQ slid 0.32% to $15,580.87, after two sequential sessions in a row of losses, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, BOQI International Medical has a trailing twelve months EPS of $-6.39.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -103.78%.

Volume

Today’s last reported volume for BOQI International Medical is 94591 which is 188.2% above its average volume of 32821.

Moving Average

BOQI International Medical’s worth is way higher than its 50-day moving average of $2.42 and way higher than its 200-day moving average of $1.89.

More news about BOQI International Medical.

6. Antero Resources (AR) – 9.46%

Antero Resources Corporation, an independent oil and natural gas company, engages in the development, production, exploration, and acquisition of natural gas, natural gas liquids (NGLs), and oil properties in the United States. It operates in three segments: Exploration and Development; Marketing; and Equity Method Investment in Antero Midstream. As of December 31, 2023, the company had approximately 515,000 net acres in the Appalachian Basin; and approximately 172,000 net acres in the Upper Devonian Shale. Its gathering and compression systems also comprise 631 miles of gas gathering pipelines in the Appalachian Basin. The company was formerly known as Antero Resources Appalachian Corporation and changed its name to Antero Resources Corporation in June 2013. Antero Resources Corporation was incorporated in 2002 and is headquartered in Denver, Colorado.

NYSE ended the session with Antero Resources rising 9.46% to $25.62 on Wednesday while NYSE jumped 0.15% to $17,365.99.

Earnings Per Share

As for profitability, Antero Resources has a trailing twelve months EPS of $0.78.

PE Ratio

Antero Resources has a trailing twelve months price to earnings ratio of 32.85. Meaning, the purchaser of the share is investing $32.85 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.8%.

Volatility

Antero Resources’s last week, last month’s, and last quarter’s current intraday variation average was 6.40%, 0.42%, and 1.95%.

Antero Resources’s highest amplitude of average volatility was 6.40% (last week), 2.02% (last month), and 1.95% (last quarter).

More news about Antero Resources.

7. Garmin (GRMN) – 8.85%

Garmin Ltd. designs, develops, manufactures, markets, and distributes a range of wireless devices in the Americas, the Asia Pacific, Australian Continent, Europe, the Middle East, and Africa. Its Fitness segment offers running and multi-sport watches; cycling products; activity tracking and smartwatch devices; fitness and cycling accessories. This segment also provides Garmin Connect and Garmin Connect Mobile, which are web and mobile platforms; and Connect IQ, an application development platform. The company's Outdoor segment offers adventure watches, outdoor handhelds, golf devices and mobile apps, and dog tracking and training devices. Its Aviation segment designs, manufactures, and markets various aircraft avionics solutions comprising integrated flight decks, electronic flight displays and instrumentation, navigation and communication products, automatic flight control systems and safety-enhancing technologies, audio control systems, engine indication systems, traffic awareness and avoidance solutions, ADS-B and transponder solutions, weather information and avoidance solutions, datalink and connectivity solutions, portable GPS navigators and wearables, and various services products. The company's Marine segment provides chartplotters and multi-function displays, cartography products, fishfinders, sonar products, autopilot systems, radars, compliant instrument displays and sensors, VHF communication radios, handhelds and wearable devices, sailing products, entertainment, digital switching products, and trolling motors. Its Auto segment offers embedded domain controllers and infotainment systems; personal navigation devices; and cameras. The company sells its products through independent retailers, dealers, distributors, installation and repair shops, and original equipment manufacturers, as well as an online webshop, garmin.com. Garmin Ltd. was founded in 1989 and is based in Schaffhausen, Switzerland.

NASDAQ ended the session with Garmin rising 8.85% to $133.61 on Wednesday, following the last session’s upward trend. NASDAQ fell 0.32% to $15,580.87, after two consecutive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Garmin (grmn) Q4 earnings: how key metrics compare to wall street estimatesHere is how Garmin performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Earnings Per Share

As for profitability, Garmin has a trailing twelve months EPS of $5.43.

PE Ratio

Garmin has a trailing twelve months price to earnings ratio of 24.61. Meaning, the purchaser of the share is investing $24.61 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.02%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Mar 14, 2024, the estimated forward annual dividend rate is 2.92 and the estimated forward annual dividend yield is 2.39%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Garmin’s EBITDA is 58.96.

More news about Garmin.

8. AC Immune SA (ACIU) – 8.82%

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

NASDAQ ended the session with AC Immune SA rising 8.82% to $3.33 on Wednesday, after four sequential sessions in a row of gains. NASDAQ fell 0.32% to $15,580.87, after two successive sessions in a row of losses, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, AC Immune SA has a trailing twelve months EPS of $-0.93.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -43.23%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

AC Immune SA’s EBITDA is -9.56.

Volume

Today’s last reported volume for AC Immune SA is 139627 which is 2.18% below its average volume of 142744.

More news about AC Immune SA.

9. Southwestern Energy (SWN) – 7.34%

Southwestern Energy Company, an independent energy company, engages in the exploration, development, and production of natural gas, oil, and natural gas liquids (NGLs) in the United States. It operates through two segments, Exploration and Production, and Marketing. The company focuses on the development of unconventional natural gas and oil reservoirs located in Pennsylvania, West Virginia, Ohio, and Louisiana. It also engages in the marketing and transportation of natural gas, oil, and NGLs. The company serves LNG exporters, energy companies, utilities, and industrial purchasers of natural gas. Southwestern Energy Company was incorporated in 1929 and is headquartered in Spring, Texas.

NYSE ended the session with Southwestern Energy rising 7.34% to $7.09 on Wednesday, following the last session’s downward trend. NYSE rose 0.15% to $17,365.99, after two successive sessions in a row of losses, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Southwestern Energy has a trailing twelve months EPS of $4.61.

PE Ratio

Southwestern Energy has a trailing twelve months price to earnings ratio of 1.54. Meaning, the purchaser of the share is investing $1.54 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 128.69%.

More news about Southwestern Energy.

10. Akari Therapeutics Plc (AKTX) – 6.7%

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

NASDAQ ended the session with Akari Therapeutics Plc jumping 6.7% to $2.39 on Wednesday, following the last session’s upward trend. NASDAQ fell 0.32% to $15,580.87, after two successive sessions in a row of losses, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Akari Therapeutics Plc has a trailing twelve months EPS of $-2.52.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -178.09%.

Moving Average

Akari Therapeutics Plc’s worth is way below its 50-day moving average of $2.78 and way under its 200-day moving average of $3.41.

Volume

Today’s last reported volume for Akari Therapeutics Plc is 967 which is 89.22% below its average volume of 8976.

More news about Akari Therapeutics Plc.

Losers Today

1. Palo Alto Networks (PANW) – -28.38%

Palo Alto Networks, Inc. provides cybersecurity solutions worldwide. The company offers firewall appliances and software; and Panorama, a security management solution for the global control of network security platform as a virtual or a physical appliance. It also provides subscription services covering the areas of threat prevention, malware and persistent threat, URL filtering, laptop and mobile device protection, DNS security, Internet of Things security, SaaS security API, and SaaS security inline, as well as threat intelligence, and data loss prevention. In addition, the company offers cloud security, secure access, security operations, and threat intelligence and security consulting; professional services, including architecture design and planning, implementation, configuration, and firewall migration; education services, such as certifications, as well as online and in-classroom training; and support services. It sells its products and services through its channel partners, as well as directly to medium to large enterprises, service providers, and government entities operating in various industries, including education, energy, financial services, government entities, healthcare, Internet and media, manufacturing, public sector, and telecommunications. Palo Alto Networks, Inc. was incorporated in 2005 and is headquartered in Santa Clara, California.

NYSE ended the session with Palo Alto Networks sliding 28.38% to $262.18 on Wednesday, after three consecutive sessions in a row of losses. NYSE jumped 0.15% to $17,365.99, after two consecutive sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Palo Alto Networks has a trailing twelve months EPS of $6.45.

PE Ratio

Palo Alto Networks has a trailing twelve months price to earnings ratio of 40.65. Meaning, the purchaser of the share is investing $40.65 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 45.84%.

Moving Average

Palo Alto Networks’s value is way under its 50-day moving average of $324.11 and above its 200-day moving average of $258.65.

Volume

Today’s last reported volume for Palo Alto Networks is 42128100 which is 1025.85% above its average volume of 3741860.

More news about Palo Alto Networks.

2. Matterport
(MTTR) – -18.44%

Matterport, Inc., a spatial data company, focuses on digitization and datafication of the built world. The company offers Matterport Capture Services, a fully managed solution for enterprise subscribers; Smartphone Capture, a smartphone capture solution for both iOS and Android; Matterport Pro3, a 3D camera that scans properties; Matterport Pro2, a 3D camera that captures spaces; and 360 Cameras. It also provides Matterport Axis, a motorized mount that can be used with the Matterport Capture app to capture 3D digital twins of any physical space with increased speed, precision, and consistency. It offers solutions for residential and commercial real estate, facilities management and retail, AEC, insurance and repair, and travel and hospitality. Matterport, Inc. is headquartered in Sunnyvale, California.

NASDAQ ended the session with Matterport
dropping 18.44% to $2.07 on Wednesday, after two successive sessions in a row of gains. NASDAQ slid 0.32% to $15,580.87, after two successive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Matterport
has a trailing twelve months EPS of $-0.73.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -37.61%.

Yearly Top and Bottom Value

Matterport
‘s stock is valued at $2.07 at 16:32 EST, way under its 52-week high of $3.78 and way above its 52-week low of $1.84.

Revenue Growth

Year-on-year quarterly revenue growth grew by 7%, now sitting on 159.34M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Matterport
‘s EBITDA is -4.72.

More news about Matterport
.

3. Matterport
(MTTR) – -18.44%

Matterport, Inc., a spatial data company, focuses on digitization and datafication of the built world. The company offers Matterport Capture Services, a fully managed solution for enterprise subscribers; Smartphone Capture, a smartphone capture solution for both iOS and Android; Matterport Pro3, a 3D camera that scans properties; Matterport Pro2, a 3D camera that captures spaces; and 360 Cameras. It also provides Matterport Axis, a motorized mount that can be used with the Matterport Capture app to capture 3D digital twins of any physical space with increased speed, precision, and consistency. It offers solutions for residential and commercial real estate, facilities management and retail, AEC, insurance and repair, and travel and hospitality. Matterport, Inc. is headquartered in Sunnyvale, California.

NASDAQ ended the session with Matterport
sliding 18.44% to $2.07 on Wednesday while NASDAQ fell 0.32% to $15,580.87.

Earnings Per Share

As for profitability, Matterport
has a trailing twelve months EPS of $-0.73.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -37.61%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Matterport
‘s EBITDA is -4.72.

Moving Average

Matterport
‘s worth is way under its 50-day moving average of $2.45 and way under its 200-day moving average of $2.62.

Volatility

Matterport
‘s last week, last month’s, and last quarter’s current intraday variation average was 2.92%, 0.55%, and 3.08%.

Matterport
‘s highest amplitude of average volatility was 2.92% (last week), 3.44% (last month), and 3.08% (last quarter).

More news about Matterport
.

4. Avinger (AVGR) – -17.97%

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.

NASDAQ ended the session with Avinger sliding 17.97% to $4.39 on Wednesday, following the last session’s upward trend. NASDAQ fell 0.32% to $15,580.87, after two sequential sessions in a row of losses, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Avinger has a trailing twelve months EPS of $-30.21.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -973.16%.

Yearly Top and Bottom Value

Avinger’s stock is valued at $4.39 at 16:32 EST, way below its 52-week high of $19.65 and way higher than its 52-week low of $2.50.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Avinger’s EBITDA is -4.09.

More news about Avinger.

5. AirNet Technology (ANTE) – -16.53%

AirNet Technology Inc. operates out-of-home advertising platforms in the People's Republic of China. The company provides advertising time slots in the form of digital TV screens on airplanes; and media contents display in air travel; and gas station media network. It also displays non-advertising content, including comedy clips, movie, TV series, sports, local attractions, reality shows, commentaries, and documentaries. In addition, the company develops and operates outdoor advertising platforms in gas stations, such as LED screens, billboards, and light boxes. Further, it operates CIBN-AirNet channel to broadcast network TV programs to air travelers. The company was formerly known as AirMedia Group Inc. AirNet Technology Inc. was founded in 2005 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with AirNet Technology dropping 16.53% to $1.01 on Wednesday, following the last session’s downward trend. NASDAQ dropped 0.32% to $15,580.87, after two sequential sessions in a row of losses, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, AirNet Technology has a trailing twelve months EPS of $-2.54.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1630.89%.

Moving Average

AirNet Technology’s value is way higher than its 50-day moving average of $0.78 and above its 200-day moving average of $1.01.

Revenue Growth

Year-on-year quarterly revenue growth declined by 78.4%, now sitting on 918k for the twelve trailing months.

Volume

Today’s last reported volume for AirNet Technology is 85186 which is 128.95% above its average volume of 37206.

Yearly Top and Bottom Value

AirNet Technology’s stock is valued at $1.01 at 16:32 EST, way below its 52-week high of $1.87 and way above its 52-week low of $0.56.

More news about AirNet Technology.

6. Aptorum Group Limited (APM) – -16.06%

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

NASDAQ ended the session with Aptorum Group Limited dropping 16.06% to $1.62 on Wednesday, following the last session’s downward trend. NASDAQ slid 0.32% to $15,580.87, after two successive sessions in a row of losses, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Aptorum Group Limited has a trailing twelve months EPS of $-3.65.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -108.34%.

Yearly Top and Bottom Value

Aptorum Group Limited’s stock is valued at $1.62 at 16:32 EST, way below its 52-week high of $9.00 and way above its 52-week low of $1.35.

Moving Average

Aptorum Group Limited’s worth is way under its 50-day moving average of $1.90 and way below its 200-day moving average of $2.24.

Volume

Today’s last reported volume for Aptorum Group Limited is 6733 which is 3.6% below its average volume of 6985.

Revenue Growth

Year-on-year quarterly revenue growth declined by 18.2%, now sitting on 1.2M for the twelve trailing months.

More news about Aptorum Group Limited.

7. Zscaler (ZS) – -14.41%

Zscaler, Inc. operates as a cloud security company worldwide. The company offers Zscaler Internet Access solution that provides users, workloads, IoT, and OT devices secure access to externally managed applications, including software-as-a-service (SaaS) applications and internet destinations; and Zscaler Private Access solution, which is designed to provide access to managed applications hosted internally in data centers, and private or public clouds. It also provides Zscaler Digital Experience that measures end-to-end user experience across business applications, as well as provides an easy-to-understand digital experience score for each user, application, and location within an enterprise. In addition, the company offers Posture Control solutions comprising Cloud Security Posture Management that identifies and remediates application misconfigurations in SaaS, infrastructure as a service, and PaaS to reduce risk and ensure compliance with industry and organizational benchmarks; Cloud Infrastructure Entitlement Management that detects and remediates excessive or unused cloud permissions and enforces least privileged access without disrupting productivity; Infrastructure as Code (IaC), which analyzes IaC templates to identify misconfigurations and other security issues prior to deployment to cloud infrastructure; and Vulnerability Scanning and Data Loss Prevention solutions. Its platform modules include Zscaler Central Authority, Zscaler Enforcement Node, and Zscaler Log Servers. The company serves customers in airlines and transportation, conglomerates, consumer goods and retail, financial services, healthcare, manufacturing, media and communications, public sector and education, technology, and telecommunications services industries. The company was formerly known as SafeChannel, Inc., and changed its name to Zscaler, Inc. in August 2008. Zscaler, Inc. was incorporated in 2007 and is headquartered in San Jose, California.

NASDAQ ended the session with Zscaler falling 14.41% to $213.16 on Wednesday while NASDAQ slid 0.32% to $15,580.87.

Earnings Per Share

As for profitability, Zscaler has a trailing twelve months EPS of $-1.15.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -27.07%.

Moving Average

Zscaler’s value is under its 50-day moving average of $228.69 and way above its 200-day moving average of $171.65.

Volatility

Zscaler’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.10%, a positive 0.18%, and a positive 1.68%.

Zscaler’s highest amplitude of average volatility was 0.10% (last week), 2.24% (last month), and 1.68% (last quarter).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Zscaler’s EBITDA is -4.27.

Previous days news about Zscaler

• Zscaler (zs) declines more than market: some information for investors. According to Zacks on Tuesday, 20 February, "Market participants will be closely following the financial results of Zscaler in its upcoming release. ", "In terms of valuation, Zscaler is presently being traded at a Forward P/E ratio of 102.36. "

More news about Zscaler.

8. ATIF Holdings Limited (ATIF) – -14.16%

ATIF Holdings Limited, a consulting company, provides financial consulting services to small and medium-sized enterprises in Asia. It primarily helps clients going public on the OTC markets and exchanges in the United States. The company was incorporated in 2015 and is headquartered in Rancho Cucamonga, California.

NASDAQ ended the session with ATIF Holdings Limited dropping 14.16% to $0.97 on Wednesday, following the last session’s downward trend. NASDAQ fell 0.32% to $15,580.87, after two successive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, ATIF Holdings Limited has a trailing twelve months EPS of $-0.35.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -130.01%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

ATIF Holdings Limited’s EBITDA is -21.72.

Volume

Today’s last reported volume for ATIF Holdings Limited is 1729 which is 91.69% below its average volume of 20828.

Revenue Growth

Year-on-year quarterly revenue growth declined by 58.3%, now sitting on 2.27M for the twelve trailing months.

Moving Average

ATIF Holdings Limited’s value is under its 50-day moving average of $0.98 and way below its 200-day moving average of $1.30.

More news about ATIF Holdings Limited.

9. Aravive (ARAV) – -13.39%

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain AVB-500 as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.

NASDAQ ended the session with Aravive sliding 13.39% to $0.04 on Wednesday while NASDAQ dropped 0.32% to $15,580.87.

Earnings Per Share

As for profitability, Aravive has a trailing twelve months EPS of $-0.76.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -475.98%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Aravive’s EBITDA is 0.65.

Moving Average

Aravive’s worth is way below its 50-day moving average of $0.10 and way under its 200-day moving average of $0.59.

More news about Aravive.

10. Canaan (CAN) – -12.79%

Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has operations in the United States, Australia, Kazakhstan, Hong Kong, Canada, Mainland China, Thailand, Sweden, and internationally. Canaan Inc. was founded in 2013 and is based in Singapore.

NASDAQ ended the session with Canaan dropping 12.79% to $1.88 on Wednesday while NASDAQ slid 0.32% to $15,580.87.

Earnings Per Share

As for profitability, Canaan has a trailing twelve months EPS of $-0.47.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.23%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Canaan’s stock is considered to be overbought (>=80).

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 30.8% and 75%, respectively.

Volatility

Canaan’s last week, last month’s, and last quarter’s current intraday variation average was 0.45%, 1.02%, and 7.58%.

Canaan’s highest amplitude of average volatility was 0.88% (last week), 7.50% (last month), and 7.58% (last quarter).

Sales Growth

Canaan’s sales growth is negative 38.4% for the ongoing quarter and negative 20.2% for the next.

More news about Canaan.

Stay up to date with our winners and losers daily report